Researchers have been excited about the medication , a innovative dual agonist showing remarkable results in clinical trials for size reduction . It functions by targeting both pathways : GLP-1 and GIP, that , when stimulated, assist influence appetite and improve energy expenditure . Early reports suggest substantial body loss and possible improve